MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results

被引：1

作者：

Migliorini, D. ^{[1
]}

Vernet, R. ^{[2
]}

Belkouch, M. C. ^{[2
]}

Luy, P. ^{[2
]}

Blaser, S. ^{[1
]}

Ancrenaz, V. ^{[1
]}

Blazek, N. ^{[1
]}

Grandjean, N. ^{[1
]}

Wasem, J. ^{[1
]}

Janin, B. ^{[3
]}

Harboe-Schmidt, P. ^{[3
]}

Grogg, J. ^{[3
]}

Bouche, N. ^{[4
]}

Mach, N. ^{[1
,2
]}

机构：

[1] Fdn Dr Henri Dubois Ferriere Dinu Lipatti, Clin Res Unit, Geneva, Switzerland

[2] Ctr Oncol, Cell Therapy Lab, Geneva, Switzerland

[3] MaxiVAX SA, Clin Affairs, Geneva, Switzerland

[4] Ecole Polytech Fed Lausanne, Life Sci, Lausanne, Switzerland

来源：

关键词：

D O I：

10.1016/S0959-8049(16)30332-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

531

引用

页码：S114 / S114

页数：1

共 22 条